ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

Oral presentation at ESMO Annual Meeting 2021


ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
Science & Medicine 
Read more
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
Science & Medicine 
Read more
ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
Science & Medicine 
Read more

3rd Macrophage-directed Therapies Summit

From  Sep 28, 2021  to  Sep 30, 2021 

Read more

PEGS Europe

From  Nov 02, 2021  to  Nov 04, 2021 

Read more

9th International γδ T Cell Conference

From  Nov 05, 2021  to  Nov 08, 2021 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news